Search This Blog

Monday, June 2, 2025

QIAGEN expands minimal residual disease (MRD) testing in oncology with new partnerships

 

  • Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR

  • Tracer Biotechnologies partnership to develop blood-based minimal residual disease (MRD) tests on QIAcuity digital PCR systems for solid cancer tumors

  • Collaboration with Foresight Diagnostics aims to develop a kit version of its CLARITY™ NGS assay for use in lymphoma

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)